这笔交易标志着英国制药公司的战略转型，该公司此前在影响心脏和代谢系统疾病方面的药物管线规模 较小。新任首席执行官路克·米尔斯正面临增加新药储备的压力，因为他正寻求抵消一款重磅抗艾滋病 (HIV)药物专利到期所带来的影响。 葛兰素史克目前最大的财务压力来自于其支柱性 HIV 药物（如 Dovato）将在 2028 年前后遭遇专利到 期。 1月20日，葛兰素史克还宣布收购美国上市药企RAPT Therapeutics。这家公司旗下核心资产是一款长效 抗IgE单克隆抗体JYB1904，于2024年12月从济煜医药引进，主要用于食物过敏、慢性自发性荨麻疹、 哮喘等疾病的治疗。 智通财经APP获悉，葛兰素史克(GSK.US)已同意收购 35Pharma Inc.，这是一家拥有早期高血压药物资 产的生物技术公司。此举标志着这家英国制药巨头正向心血管药物领域扩张。 葛兰素史克在周三的一份声明中表示，将以 9.5 亿美元现金收购这家私人持有的加拿大公司。 ...

Core Viewpoint - Stone Four Pharmaceutical Group has seen a nearly 3% increase in stock price following the announcement of obtaining production registration for Indobufene tablets from the National Medical Products Administration of China, indicating a significant development in their product pipeline [1] Company Summary - Stone Four Pharmaceutical Group's stock rose by 2.68% to HKD 3.06, with a trading volume of HKD 16.01 million [1] - The company has received approval for Indobufene tablets (0.2g), classified as a Class 3 chemical drug, which is considered equivalent to passing the consistency evaluation [1] Product Summary - Indobufene tablets are primarily used for treating ischemic cardiovascular diseases caused by arteriosclerosis, ischemic cerebrovascular diseases, and venous thrombosis, and can also prevent thrombosis during hemodialysis [1] - Developed by an Italian company, Indobufene has become a substitute for aspirin in patients who are intolerant to it [1] Market Summary - According to the MoSheng Pharmaceutical Database, the total hospital sales of Indobufene tablets exceeded 1 billion in 2022, showing a year-on-year growth over the past three years [1] - Sales are projected to surpass 1.9 billion in 2024, reflecting a year-on-year increase of 37.47%, and exceed 1.1 billion in the first half of 2025, with a year-on-year growth of 28.07% [1] - The high sales figures have attracted attention from numerous pharmaceutical companies, intensifying market competition [1]